Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Int J Pharm ; 476(1-2): 205-12, 2014 Dec 10.
Article in English | MEDLINE | ID: mdl-25280884

ABSTRACT

We recently demonstrated that Doxil loses its long-circulating properties when injected repeatedly at doses below 2 mg/m(2) in dogs. In studies using other animal species, PEGylated liposomal doxorubicin has been reported not to induce the accelerated blood clearance (ABC) phenomenon. We investigated the issue of whether Doxil can elicit the ABC phenomenon in several species. In minipigs, the ABC phenomenon was induced at 2 mg/m(2). In other animal species, the ABC phenomenon was not observed at higher doses (>2 mg/m(2)), but was observed at much lower doses (0.2 mg/m(2)). The pharmacokinetic profile of a second dose of Doxil reflected the circulating anti-PEG IgM level induced by the first dose. The ABC phenomenon was not observed at the clinically recommended DXR dose (20 mg/m(2)) in any animal species. These results indicate that Doxil can cause the ABC phenomenon in all animals tested, the extent of induction was dependent on the first dose of Doxil, and a higher Doxil dose lessened the ABC phenomenon. The current study results suggest that a careful study design including selection of animal species is important for preclinical studies using PEGylated liposomal formulations even if they contain anticancer drugs that suppress the host immune response.


Subject(s)
Antibiotics, Antineoplastic/pharmacokinetics , Doxorubicin/analogs & derivatives , Immunoglobulin M/immunology , Animals , Antibiotics, Antineoplastic/administration & dosage , Dose-Response Relationship, Drug , Doxorubicin/administration & dosage , Doxorubicin/pharmacokinetics , Macaca fascicularis , Male , Mice , Mice, Inbred BALB C , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/pharmacokinetics , Rats , Rats, Wistar , Species Specificity , Swine , Swine, Miniature
2.
Biol Pharm Bull ; 36(11): 1842-8, 2013.
Article in English | MEDLINE | ID: mdl-24189428

ABSTRACT

We have reported that PEGylated liposomes lose their long-circulating properties when injected twice into the same animal within a certain interval (the accelerated blood clearance (ABC) phenomenon). We assumed that this phenomenon was triggered via the abundant secretion of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) in response to the first dose of PEGylated liposomes and that the spleen played an important role in the production of anti-PEG IgM. However, no direct evidence has yet confirmed this suspicion. In the current study, we verified, both in vitro and ex vivo, that spleen cells are indeed responsible for the production of anti-PEG IgM in response to PEGylated liposomes. In this study, spleen cells obtained from either naïve mice or mice pre-treated with PEGylated liposomes induced the production of anti-PEG IgM in a dose- and time-dependent manner, upon incubation with PEGylated liposomes. In addition, we confirmed that among the different fractions of splenic B cells, IgM-positive B cells, rather than CD45R-positive or CD19-positive splenic B cells, which are presumed to be the marginal zone B (MZB) cells, are the major cells producing anti-PEG IgM in the response to stimulation by PEGylated liposomes. These results may provide new insights into the mechanisms underlying the anti-PEG IgM production in response to the stimulation by PEGylated liposomes.


Subject(s)
B-Lymphocytes/immunology , Immunoglobulin M/immunology , Liposomes/immunology , Polyethylene Glycols , Spleen/cytology , Animals , Cells, Cultured , Liposomes/chemistry , Male , Mice , Mice, Inbred BALB C , Polyethylene Glycols/chemistry
3.
Methods Mol Biol ; 948: 35-47, 2013.
Article in English | MEDLINE | ID: mdl-23070762

ABSTRACT

For the systemic application of nucleic acids such as plasmid DNA and small interfering RNA, safe and efficient carriers that overcome the poor pharmacokinetic properties of nucleic acids are required. A cationic liposome that can formulate lipoplexes with nucleic acids has significant promise as an efficient delivery system in gene therapy. To achieve in vivo stability and long circulation, most lipoplexes are modified with PEG (PEGylation). However, we reported that PEGylated liposomes lose their long-circulating properties when they are injected repeatedly at certain intervals in the same animal. This unexpected and undesirable phenomenon is referred to as the accelerated blood clearance (ABC) phenomenon. Anti-PEG IgM produced in response to the first dose of PEGylated liposomes has proven to be a major cause of the ABC phenomenon. Therefore, in a repeated dosing schedule, the detection of anti-PEG IgM in an animal treated with PEGylated lipoplex could be essential to predict the occurrence of the ABC phenomenon. This chapter introduces a method for the evaluation of serum anti-PEG IgM by a simple ELISA procedure, and describes some precautions associated with this method.


Subject(s)
DNA/metabolism , Enzyme-Linked Immunosorbent Assay/methods , Immunoglobulin M/blood , Nanostructures/chemistry , Polyethylene Glycols/chemistry , Polyethylene Glycols/metabolism , RNA, Small Interfering/metabolism , Animals , DNA/administration & dosage , Drug Carriers/chemistry , Horseradish Peroxidase/metabolism , Immunoglobulin M/immunology , Immunoglobulin M/metabolism , Liposomes , Male , Mice , Mice, Inbred BALB C , RNA, Small Interfering/administration & dosage
4.
Int J Pharm ; 438(1-2): 176-83, 2012 Nov 15.
Article in English | MEDLINE | ID: mdl-22944302

ABSTRACT

We previously developed a PEG-coated cationic liposome that enabled dual targeting delivery of oxaliplatin (l-OHP) to both tumor endothelial cells and tumor cells in a solid tumor. The targeted liposomal l-OHP formulation consequently elicited potent antitumor efficacy in a murine solid tumor model after 3 sequential injections. However, the probable mechanism(s) for this enhanced antitumor activity has not been fully elucidated. In the present study, therefore, the changes in tumor microenvironment induced by sequential administration of liposomal l-OHP were investigated, with emphasis on its impact to the intratumoral localization of the subsequently injected dose. In addition, the potential for anti-PEG IgM production upon repeated administration of liposomal l-OHP-containing PEGylated lipid was clearly revealed. Two sequential injections of liposomal l-OHP induced superior apoptotic activity in tumor tissue and thus resulted in broader intratumor distribution of the subsequent test dose of PEG-coated cationic liposomes, compared with a single injection of liposomal l-OHP. In addition, it was confirmed that repeated administration of liposomal l-OHP did not induce a significant anti-PEG IgM response, indicating that l-OHP encapsulated in PEG-coated liposomes was efficient in abrogating the ABC phenomenon. These results suggest that sequential treatment strategies with liposomal cytotoxic agents might be superior to mono-treatment strategies in achieving alterations in the tumor microenvironment and maintaining/restoring the pharmacokinetics of the formulation, and, therefore, would result in substantial therapeutic efficacy.


Subject(s)
Antineoplastic Agents/administration & dosage , Neoplasms/drug therapy , Organoplatinum Compounds/administration & dosage , Polyethylene Glycols/administration & dosage , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Apoptosis/drug effects , Cell Line, Tumor , Immunoglobulin M/immunology , Liposomes , Male , Mice , Mice, Inbred C57BL , Neoplasms/metabolism , Organoplatinum Compounds/chemistry , Organoplatinum Compounds/pharmacokinetics , Oxaliplatin , Polyethylene Glycols/chemistry , Tissue Distribution , Treatment Outcome
5.
Int J Pharm ; 436(1-2): 636-43, 2012 Oct 15.
Article in English | MEDLINE | ID: mdl-22850293

ABSTRACT

The accelerated blood clearance phenomenon involving anti-PEG IgM production has been recognized as an important issue for the design and development of PEGylated liposomes. Here, we show that empty PEGylated liposomes and Doxil, PEGylated liposomes containing doxorubicin, both caused anti-PEG IgM production and thereby a rapid clearance of the second and/or third dose of Doxil in Beagle dogs in a lipid-dose, inverse-dependent manner. It appears that the pharmacokinetic profile of the second and third administration of Doxil reflected the presence of anti-PEG IgM circulating in the blood. Doxil plus an excess amount of empty PEGylated liposomes rather enhanced the production of anti-PEG IgM compared to Doxil of the same doxorubicin dose. During sequential administration, increasing the lipid dose of Doxil in each dose by the addition of empty PEGylated liposomes strongly attenuated the magnitude of the ABC phenomenon during the effectuation phase of a second and third dose of Doxil. Our results suggest that the pre-clinical study of anti-cancer drug-containing PEGylated liposomes with dogs must be carefully designed and performed with monitoring of the anti-PEG IgM and liposomal drugs circulating in the blood.


Subject(s)
Antibiotics, Antineoplastic/blood , Doxorubicin/blood , Polyethylene Glycols/pharmacokinetics , Animals , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/pharmacokinetics , Dogs , Doxorubicin/administration & dosage , Doxorubicin/pharmacokinetics , Immunoglobulin M/blood , Liposomes , Male , Polyethylene Glycols/administration & dosage , Rats , Rats, Wistar
6.
Biol Pharm Bull ; 35(8): 1336-42, 2012.
Article in English | MEDLINE | ID: mdl-22863934

ABSTRACT

A single intravenous administration of polyethylene glycol-coated (PEGylated) bovine serum albumin (BSA) and ovalbumin (OVA) elicited an anti-PEG immunoglobulin M (IgM) response, similar to that from PEGylated liposomes, although the administration did not elicit specific neutralizing antibodies to BSA and OVA. A cross-reactivity was observed between anti-PEG IgMs elicited by PEG-BSA and PEGylated liposomes. The anti-PEG IgM level induced by PEGylated proteins (BSA and OVA) reached the maximum at day 5 following intravenous injection. This production pattern was consistent with that induced by PEGylated liposomes. Splenectomy suppressed the anti-PEG IgM response against PEG-BSA and PEGylated liposomes. These observations relating PEG-BSA and PEGylated liposomes indicate that PEGylated proteins might promote the immune responses against PEG with a mechanism similar to that of PEGylated liposomes. In addition, a single intravenous administration of PEGylated adenovirus (PEG-Ad) also elicited an anti-PEG IgM response in a PEG-modification ratio dependent manner. To the best of our knowledge, this is the first report showing that an intravenous administration can elicit an anti-PEG IgM response against PEGylated substances. It appears that anti-PEG IgMs can be produced by the systemic administration of a PEGylated substance and may limit the efficacy of PEGylated substances such as proteins, Ad vector and nanoparticles, due to a cross-reactivity seen in some patients. The immunogenicity of PEGylated substances is usually tested against those very substances, rather than against covalently attached PEG. Our study suggests that the PEG immunogenicity of PEGylated therapeutic agents and particles merits further investigation.


Subject(s)
Adenoviridae/immunology , Immunoglobulin M/metabolism , Ovalbumin/pharmacology , Polyethylene Glycols/pharmacology , Serum Albumin/pharmacology , Animals , Cattle , Injections, Intravenous , Liposomes/immunology , Liposomes/pharmacology , Male , Ovalbumin/administration & dosage , Ovalbumin/immunology , Polyethylene Glycols/administration & dosage , Rats , Rats, Wistar , Serum Albumin/administration & dosage , Serum Albumin/immunology , Splenectomy
7.
Int J Pharm ; 426(1-2): 263-270, 2012 Apr 15.
Article in English | MEDLINE | ID: mdl-22310465

ABSTRACT

Combination therapy with 2 or more drugs with different mechanisms of action has been considered a promising strategy for the effective treatment of advanced and metastatic cancers. However, the rational design of combination therapy represents a potential prerequisite for its effectiveness. Recently, we showed that the combination of oral metronomic S-1 dosing with oxaliplatin (l-OHP)-containing PEG-coated "neutral" liposomes exerted excellent antitumor activity. In addition, we recently designed a PEG-coated "cationic" liposome for dual-targeting delivery of l-OHP to tumor endothelial cells and tumor cells in a solid tumor. This targeted liposomal l-OHP formulation showed efficient antitumor activity in a murine tumor model, compared with l-OHP-containing PEG-coated "neutral" liposomes. In the present study, we investigated the issue of whether metronomic S-1 dosing with l-OHP-containing PEG-coated "cationic" liposomes creates synergy. Unfortunately, metronomic S-1 dosing resulted in impaired delivery of PEG-coated "cationic" liposomes into tumor tissue, presumably by decreasing the binding sites on tumor blood vessels available for the liposomes. The anticipated cytotoxic synergistic effect of the combination treatment was not achieved. Instead, the combination treatment showed lower antitumor efficacy than l-OHP-containing PEG-coated "cationic" liposomes alone. These results suggest that the combined treatment of S-1 and l-OHP-containing PEG-coated "cationic" liposomes seems to be antagonistic rather than synergistic.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Colorectal Neoplasms/drug therapy , Neovascularization, Pathologic/prevention & control , Polyethylene Glycols/chemistry , Administration, Metronomic , Angiogenesis Inhibitors/administration & dosage , Animals , Antineoplastic Combined Chemotherapy Protocols/blood , Antineoplastic Combined Chemotherapy Protocols/chemistry , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Biological Availability , Cell Line, Tumor , Chemistry, Pharmaceutical , Colorectal Neoplasms/blood , Colorectal Neoplasms/blood supply , Colorectal Neoplasms/pathology , Drug Antagonism , Drug Combinations , Drug Compounding , Drug Synergism , Injections, Intravenous , Liposomes , Male , Mice , Mice, Inbred BALB C , Nanotechnology , Neovascularization, Pathologic/blood , Neovascularization, Pathologic/pathology , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Oxonic Acid/administration & dosage , Particle Size , Technology, Pharmaceutical/methods , Tegafur/administration & dosage , Tissue Distribution
8.
Cancer Sci ; 101(11): 2470-5, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20731663

ABSTRACT

Metronomic chemotherapy has been advocated recently as a novel chemotherapeutic regimen. Polyethylene glycol (PEG)-coated liposomes are well known to accumulate in solid tumors by virtue of the highly permeable angiogenic blood vessels characteristic for growing tumor tissue, the so-called "enhanced permeability and retention (EPR) effect". To expand the range of applications and investigate the clinical value of the combination strategy, the therapeutic benefit of metronomic S-1 dosing in combination with oxaliplatin (l-OHP)-containing PEG-coated liposomes was evaluated in a murine colon carcinoma-bearing mice model. S-1 is an oral fluoropyrimidine formulation and metronomic S-1 dosing is a promising alternative to infused 5-FU in colorectal cancer therapy. Therefore, the combination of S-1 with l-OHP may be an alternative to FOLFOX (infusional 5-FU/leucovorin (LV) in combination with l-OHP), which is a first-line therapeutic regimen of a colorectal carcinoma. The combination of oral metronomic S-1 dosing with intravenous administration of liposomal l-OHP formulation exerted excellent antitumor activity without severe overlapping side-effects, compared with either metronomic S-1 dosing, free l-OHP or liposomal l-OHP formulation alone or metronomic S-1 dosing plus free l-OHP. We confirmed that the synergistic antitumor effect is due to prolonged retention of l-OHP in the tumor on account of the PEG-coated liposomes, presumably via alteration of the tumor microenvironment caused by the metronomic S-1 treatment. The combination regimen proposed here may be a breakthrough in treatment of intractable solid tumors and an alternative to FOLFOX in advanced colorectal cancer therapy with acceptable tolerance and preservation of quality of life (QOL).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/drug therapy , Disease Models, Animal , Tumor Burden/drug effects , Animals , Antineoplastic Combined Chemotherapy Protocols/chemistry , Cell Line, Tumor , Colorectal Neoplasms/pathology , Dose-Response Relationship, Drug , Drug Combinations , Drug Synergism , Humans , Liposomes , Male , Mice , Mice, Inbred BALB C , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Oxonic Acid/administration & dosage , Polyethylene Glycols/chemistry , Tegafur/administration & dosage , Treatment Outcome
9.
Pharmaceutics ; 3(1): 1-11, 2010 Dec 27.
Article in English | MEDLINE | ID: mdl-24310423

ABSTRACT

We have reported that PEGylated liposomes lose their long-circulating properties when they are administered repeatedly at certain intervals to the same animal. This unexpected phenomenon is referred to as the accelerated blood clearance (ABC) phenomenon. We recently showed that the ABC phenomenon is triggered via the abundant secretion of anti-PEG IgM in response to the first dose of PEGylated liposomes. However, the details of the underlying mechanism for the induction of anti-PEG IgM production are yet to be elucidated. The present study demonstrated that the spleen is a major organ involved in the secretion of anti-PEG IgM in mice and rats. Anti-PEG IgM production was detected in nude, T-cell deficient mice, but not in SCID mice with B- and T-cell deficiencies. These observations indicate that splenic B-cells secret anti-PEG IgM without help from T-cells. Sequential injections of PEGylated liposomes into the same mice did not promote isotype switching from IgM to IgG. Accordingly, PEGylated liposomes may function as a type-2, T-cell-independent antigen (TI-2 antigen) during anti-PEG IgM production. Although the underlying mechanism that causes an anti-PEG IgM response against PEGylated liposomes is not yet clear, our findings give implications in revealing the anti-PEG IgM response against PEGylated liposome.

10.
Toxicology ; 232(1-2): 132-7, 2007 Mar 22.
Article in English | MEDLINE | ID: mdl-17224229

ABSTRACT

The relationship of air pollutants with the increasing prevalence of allergic diseases is a matter of concern in developed countries. In this study, the immunomodulatory effects of mono-, di-, and trimethylphenols in mice were examined as regards two aspects. First, whether or not these chemicals act as sensitizers was evaluated by local lymph node assay. Of the 13 methylphenols tested, three dimethylphenol isomers (2,4-DMP, 2,5-DMP, and 3,4-DMP) were found to induce auricular lymphocyte proliferation after dermal application on both ears of mice. Cytokine production patterns in the supernatants of cultured auricular lymphocytes from mice showed these methylphenols to be contact sensitizers. Second, the effects of methylphenols on cytokine production profiles were examined using cultured splenocytes from immunologically naive mice. Under subtoxic conditions, eight methylphenols inhibited interferon-gamma (IFN-gamma) production significantly, while the effect on intreluekin-4 (IL-4) production was moderate, resulting in higher IL-4/IFN-gamma ratios in all of the tested chemicals, with the most prominent effect shown by 2,6-DMP. These results suggest that several methylphenols, especially dimethylphenol isomers, have potencies that affect the immune system, being immunogens themselves or modulators of the Th1/Th2 cytokine balance.


Subject(s)
Immunologic Factors/pharmacology , Phenols/pharmacology , Spleen/drug effects , Spleen/immunology , Xylenes/pharmacology , Animals , Cell Growth Processes/drug effects , Immunologic Factors/immunology , Interferon-gamma/immunology , Interleukin-4/immunology , Local Lymph Node Assay , Male , Mice , Mice, Inbred BALB C , Phenols/immunology , Th1 Cells/drug effects , Th1 Cells/immunology , Th2 Cells/drug effects , Th2 Cells/immunology , Xylenes/immunology
11.
J Control Release ; 115(3): 243-50, 2006 Oct 27.
Article in English | MEDLINE | ID: mdl-17011060

ABSTRACT

It is well known that steric stabilization of the surface of liposomes by a polyethyleneglycol (PEG) conjugated lipid results in reduced recognition of the liposomes by the cells of the mononuclear phagocyte system and consequently extended circulation times of the liposomes (t1/2 approximately 20 h in rat). Recently, we reported on the "accelerated blood clearance (ABC) phenomenon", causing PEGylated liposomes to be cleared very rapidly from the circulation upon repeated injection. We also reported that abundant binding of IgM, secreted into the blood stream after the first dose and, to PEGylated liposomes, plays an essential role in the induction of the ABC phenomenon. Spleen is well known to play a central role in the immune reaction and to produce IgM following a bacterial infection. The aim of the present study was to determine whether spleen contributes to the induction of the ABC phenomenon and to unravel its role in the phenomenon. In rats that were splenectomized (surgical removal of spleen) prior to the first injection of liposomes (0.001 micromol phospholipids/kg), the ABC phenomenon was totally abolished. In these rats serum IgM concentrations as well as the amounts of IgM bound to PEGylated liposomes were substantially reduced. Splenectomy attenuated the ABC phenomenon when performed until 3 days post-first injection. Removal of the spleen 4 days post-first injection left the ABC phenomenon unchanged. This finding indicates that the immune reaction in the spleen against the PEGylated liposomes occurs during at least 2-3 days following the first administration and then IgM reactive to PEGylated liposomes is produced. The present study proves that the spleen plays a critical role in the induction phase of the ABC phenomenon. For effective clinical application, many liposomal drug formulations will require multiple injections. The ABC phenomenon described in this and several preceding papers therefore has important implications for the development and evaluation of therapeutically useful liposomal formulations requiring multiple-dose administration.


Subject(s)
Liposomes , Polyethylene Glycols/pharmacokinetics , Spleen/immunology , Animals , Antigen-Antibody Reactions , Cholesterol/analogs & derivatives , Cholesterol/blood , Cholesterol/pharmacokinetics , Complement Activation , Immunoglobulin G/blood , Immunoglobulin M/blood , Liver/metabolism , Male , Metabolic Clearance Rate , Phosphatidylethanolamines/pharmacokinetics , Radiopharmaceuticals/blood , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Wistar , Spleen/metabolism , Spleen/surgery , Splenectomy , Tissue Distribution , Tritium
12.
J Control Release ; 112(1): 15-25, 2006 May 01.
Article in English | MEDLINE | ID: mdl-16515818

ABSTRACT

Steric stabilization of the surface of liposomes by a PEG conjugated lipid results in reduced recognition of the liposomes by the cells of the mononuclear phagocyte system and consequently extended their circulation times (t(1/2) approximately 20h in rat). Recently, we reported on the "accelerated blood clearance phenomenon", causing "invisible" PEGylated liposomes to be cleared very rapidly from the circulation upon repeated injection. In addition, we reported that certain serum factor(s) secreted into the blood after the first dose of PEGylated liposomes play an essential role in the phenomenon. The aim of the present study was to identify the major serum protein(s) responsible for the phenomenon and to unravel their mode of action. The amount of protein binding to PEGylated liposomes during incubation with serum hardly correlated with the extent of the phenomenon. PEGylated liposomes incubated with serum obtained from rats pre-injected 5 days before with the same liposomes showed a much more complex pattern of bound proteins than when incubated with naïve serum, as revealed by 2D-PAGE and SDS-PAGE. Subsequent analysis with LC-MS/MS and Western blot showed that the major pre-treated serum protein binding to PEGylated liposomes was IgM. Semi-quantitative analysis showed that larger amount of IgM bound to PEGylated liposomes compared to conventional liposomes. It was further demonstrated that PEGylated liposomes could activate the complement system due to IgM binding when incubated in serum from rats pre-injected with PEGylated liposomes, while conventional liposomes were not. These findings suggest that the selective binding of IgM to the second injected PEGylated liposomes and the subsequent complement activation by IgM resulted in the accelerated clearance and enhanced hepatic uptake of the second injected PEGylated liposomes. Based on the results described here, we are drawing attention to the potential occurrence of unexpected immune reactions upon intravenous administration of PEGylated liposomes or other particles and, by extension, PEGylated proteins and DNAs.


Subject(s)
Immunoglobulin M/metabolism , Liposomes/pharmacokinetics , Polyethylene Glycols/pharmacokinetics , Animals , Complement Activation , Immunoglobulin M/immunology , Injections, Intravenous , Kupffer Cells/metabolism , Liposomes/administration & dosage , Liver/metabolism , Male , Polyethylene Glycols/administration & dosage , Protein Binding , Rats , Rats, Wistar , Spleen/metabolism
13.
J Control Release ; 105(3): 305-17, 2005 Jul 20.
Article in English | MEDLINE | ID: mdl-15908032

ABSTRACT

We recently reported that a second dose of polyethylene glycol (PEG) (M.W. 2000)-modified liposomes (mPEG2000-liposomes) is rapidly cleared from the blood and accumulates in the liver when injected twice in the same rat or mouse at several-day intervals (referred to as the "accelerated blood clearance (ABC) phenomenon"). In the present study we observed that a high dose (5 micromol/kg) of conventional liposomes (CL: without a PEG-coating) can induce the same phenomenon, while a low lipid dose (0.001 micromol/kg) did not. The induction of the phenomenon by mPEG2000-liposomes decreased with increasing first dose (0.001-5 micromol/kg). We observed a strong inverse relationship between the dose of initially injected PEG2000-liposomes and the extent to which the ABC phenomenon was induced: the higher the dose the smaller the phenomenon. Increasing the PEG density at the liposome surface beyond 5 mol% attenuated rather than induced the induction of the phenomenon, but elongation of the PEG chain length up to M.W. 5000, had no effect. In a series of hematological, serum-biochemical and histopathological safety evaluations we observed neither acute toxicity nor any signs of hepatic damage during the induction of the ABC phenomenon. Morphological examination of the liver by transmission electron microscopy (TEM) showed extensive accumulation of the second dose of mPEG2000-liposomes in the Kupffer cells, even already after 15 min, suggesting that the PEG liposomes had somehow lost the protective effect of the surface-grafted PEG against rapid clearance. The observations reported in this paper may have a considerable impact on the design and engineering of PEGylated liposomal formulations for use in multiple drug therapy.


Subject(s)
Liposomes/pharmacokinetics , Polyethylene Glycols/pharmacokinetics , ATP-Binding Cassette Transporters/biosynthesis , Animals , Biological Availability , Blood Cell Count , Excipients , Injections, Intravenous , Liposomes/chemistry , Liver/drug effects , Liver/metabolism , Male , Microscopy, Electron, Transmission , Polyethylene Glycols/chemistry , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Wistar , Structure-Activity Relationship , Surface Properties , Tissue Distribution
14.
J Control Release ; 104(1): 91-102, 2005 May 05.
Article in English | MEDLINE | ID: mdl-15866337

ABSTRACT

We have recently reported that PEGylated liposomes (PL) are cleared rapidly from the blood circulation when they are administered twice in the same rat at certain intervals, even if the liposomes are sterically stabilized by a surface modification with PEG (referred to as the accelerated blood clearance (ABC) phenomenon, J. Control. Release, 88, 35-42 (2003)). Now we report on the influence of physicochemical properties (PEG-modification, size and surface charge) of either the first or the second dose of liposomes on the ABC phenomenon. When, for the first dose, conventional liposomes (CL; without a PEG coating) of 110-nm diameter were injected, only a very slight ABC phenomenon was observed, irrespective of the liposomal surface charge: both clearance rate and hepatic accumulation of the second injected PL were only slightly enhanced compared to those of a single dose of PL. Interestingly, when for the first injection small-size liposomes (60 nm) were used, either charged or PEG-modified, but not neutral, the ABC phenomenon was clearly manifest. Apparently, the induction of the ABC phenomenon is not only determined by the PEG coating but also by the size and surface charge of the first dose of liposomes. Also when for the second dose small-size PEGylated liposomes were used, the ABC phenomenon was observed after induction by a first injection of PL, whereas plasma kinetics and organ uptake of a second dose of negatively charged CL (NCL, 110 nm) or small-sized NCL (SNCL, 60 nm) were not altered. Apparently, the PEG coating on the second dose is essential for the liposomes to be susceptible to the ABC phenomenon. The results reported here suggest that the physicochemical properties of both the first and second dose of liposomes are important either for the induction of the phenomenon or for its expression. Our observations may have a considerable impact on the clinical application and engineering of liposomal formulations for use in multiple drug therapy.


Subject(s)
Liposomes/blood , Animals , Injections, Intravenous , Liposomes/chemistry , Liposomes/pharmacokinetics , Liver/metabolism , Male , Metabolic Clearance Rate , Particle Size , Phospholipids/chemistry , Phospholipids/pharmacokinetics , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Rats , Rats, Wistar , Spleen/metabolism , Surface Properties
15.
J Control Release ; 95(3): 403-12, 2004 Mar 24.
Article in English | MEDLINE | ID: mdl-15023452

ABSTRACT

Using mice as a model, we recently reported that the long-circulating properties of polyethylene glycol (PEG) (M.W. 2000)-modified liposomes (mPEG(2000)-liposomes) disappeared when they were intravenously injected at certain intervals [referred to as the "accelerated blood clearance (ABC) phenomenon"]. Herein, we report on a study of issue of whether physicochemical properties of a prior dose of liposomes such as degree of PEGylation, PEG chain length, lipid dose, surface charge, size, play a role in inducing this phenomenon. The injection of conventional liposomes (without a PEG-coating) significantly induced the phenomenon. The PEGylation of conventional liposomes attenuated the induction of the phenomenon somewhat with increasing molar content of PEG derivative and PEG chain length. These findings clearly suggest that the PEGylation of liposomes are not the major cause of the ABC phenomenon but, rather, played a role in preventing it. In addition, increasing the lipid dose in a prior dose of mPEG(2000)-liposomes (0-25 micromol/kg) increased the induction of the phenomenon in a sigmoid manner. The surface charge and size of the liposomes were not critical for the induction of the phenomenon, although generally these serve as determinants in the biodistribution of liposomes. The results reported here clearly indicate that the physicochemical properties of a prior dose of liposomes strongly affect the pharmacokinetic behavior of a subsequent injection of mPEG(2000)-liposomes: The extent of PEGylation and the lipid dose had an effect, but the surface charge and size did not. The results reported herein have a considerable impact on the design and engineering of liposomal formulations for use in multiple drug therapy as well as in therapy that involves the use of liposomal drugs.


Subject(s)
Liposomes/administration & dosage , Metabolic Clearance Rate/drug effects , Polyethylene Glycols/administration & dosage , Animals , Chemistry, Physical/methods , Drug Administration Schedule , Injections, Intravenous , Japan , Liposomes/blood , Liposomes/pharmacokinetics , Liver/chemistry , Liver/drug effects , Male , Metabolic Clearance Rate/physiology , Mice , Mice, Inbred Strains , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/blood , Radiopharmaceuticals/pharmacokinetics , Time Factors
16.
Int J Pharm ; 255(1-2): 167-74, 2003 Apr 14.
Article in English | MEDLINE | ID: mdl-12672612

ABSTRACT

We recently reported that the firstly injected PEGylated liposomes dramatically affected the rate of blood clearance of secondly injected PEGylated liposomes in rats in a time interval of injection dependent manner [J. Control. Release (2003)]. Mice are frequently used in evaluations of the therapeutic efficacy of PEGylated liposomal formulations, but the pharmacokinetics of repeatedly injected PEGylated liposomes in mice is not fully understood. In this study, therefore, we examined in mice the effect of the repeated injection of PEGylated liposomes on their pharmacokinetics. An intravenous pretreatment with PEGylated liposomes produced a striking change in the biodistribution of the second dose which was given several days after the first injection. The first dose resulted in a reduction in the circulation half-life of the second dose. The degree of alteration was dependent on the time interval between the injections. The rapid clearance of the second dose was strongly related to hepatic clearance (CLh). This finding suggests that a considerable increase in hepatic accumulation accounts for this phenomenon. But, no liver injury or an increase in the number of Kupffer cells were detected in histopathological evaluations. Collectively, although the multiple injections of the PEGylated liposomes had no obvious physical effects, such as inflammation, their pharmacokinetic behavior was clearly altered in mice. The results obtained here have important implications not only with respect to the design and engineering of liposomes for human use, but for evaluating the therapeutic efficacy of liposomal formulations in experimental animal models as well.


Subject(s)
Cholesterol/pharmacokinetics , Phosphatidylethanolamines/pharmacokinetics , Phosphatidylglycerols/pharmacokinetics , Polyethylene Glycols/pharmacokinetics , Animals , Area Under Curve , Chemistry, Pharmaceutical , Cholesterol/administration & dosage , Cholesterol/toxicity , Dose-Response Relationship, Drug , Injections, Intravenous , Liposomes , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Metabolic Clearance Rate , Mice , Phosphatidylethanolamines/administration & dosage , Phosphatidylethanolamines/toxicity , Phosphatidylglycerols/administration & dosage , Phosphatidylglycerols/toxicity , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/toxicity , Spleen/drug effects , Spleen/metabolism , Tissue Distribution
17.
J Control Release ; 88(1): 35-42, 2003 Feb 14.
Article in English | MEDLINE | ID: mdl-12586501

ABSTRACT

Polyethylene glycol-modified liposomes (PEGylated liposomes) represent promising carrier systems for therapeutic agents. Herein, we report on a study of the effect of repeated injection of PEGylated liposomes on their pharmacokinetics in rats. The first dose resulted in a reduction in the circulation time and an increase in hepatic accumulation of the second dose in a time-interval of injection-dependent manner. No significant increases in the number of Kupffer cells were detectable, although the liver most likely played an important role in the accelerated clearance. Interestingly, the acceleration in clearance became less pronounced, when the third dose was injected at 4, 7 or 14 days after the second injection (the second dose was given 5 weeks after the first injection). An accelerated clearance was evoked in normal rats by the transfusion of serum from rats that had received PEGylated liposomes 5 days earlier, indicating that humoral serum factor(s) are also involved in causing the accelerated clearance. A complement consumption assay indicated that the complement system is not the factor. In summary, multiple injections of PEGylated liposomes clearly altered their pharmacokinetic behavior in rats. It is likely that cellular immunity (Kupffer cells) and humoral immunity are required to cause the phenomenon. The results reported here have a considerable impact in and important implications on the clinical application, design and engineering of PEGylated liposomes for use in repeated intravenous administration.


Subject(s)
Liposomes/pharmacokinetics , Polyethylene Glycols/pharmacokinetics , Animals , Cell Count , Injections, Intravenous , Kupffer Cells/drug effects , Liposomes/administration & dosage , Liver/cytology , Liver/drug effects , Liver/pathology , Male , Phosphatidylcholines , Polyethylene Glycols/administration & dosage , Rats , Rats, Wistar , Spleen/cytology , Spleen/drug effects , Spleen/metabolism , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...